Drugs / Adebellizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06172036 | Jan 2024 → Jan 2026 overdue | pancreatic neoplasm | Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adebellizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06172036 ↗ |